
BioStock Investor Pitch: Alligator Bioscience
Alligator Bioscience develops CD40 therapies for hard-to-treat cancers. The company is currently conducting a rights issue of approximately SEK 280 million to advance its leading candidate, mitazalimab, to phase III and secure a partnership. CEO Søren Bregenholt and CFO Johan Gileus visited the BioStock studio to discuss this.
Listen to CEO Søren Bregenholt and CFO Johan Gileus present the company below:

This material has been prepared for marketing purposes and is not, and should not be considered, a prospectus according to applicable laws and regulations. The complete terms of the rights issue and more information about the company have been presented in a prospectus that has been disclosed and published on the aforementioned company’s website.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.